Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

The Lancet Neurology

Volumn 12, Issue 3, 2013, Pages 233-243

  Dodel, Richard ^a   Rominger, Axel ^b   Bartenstein, Peter ^b   Barkhof, Frederik ^d   Blennow, Kaj ^e   Förster, Stefan ^b   Winter, Yaroslav ^a   Bach, Jan Philipp ^a   Popp, Julius ^f,g   Alferink, Judith ^f   Wiltfang, Jens ^h   Buerger, Katharina ^c   Otto, Markus ⁱ   Antuono, Piero ^j   Jacoby, Michael ^k   Richter, Ralph ^l   Stevens, James ^m   Melamed, Isaac ⁿ   Goldstein, Jerome ^o   Haag, Stefan ^p   Wietek, Stefan ^q   Farlow, Martin ^r   Jessen, Frank ^f,s   more..

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k Mercy Ruan Neurology Clinic   (United States)

^l Tulsa Clinical Research LLC   (United States)

^m Fort Wayne Neurological Center   (United States)

ⁿ IMMUNOe International Research Center   (United States)

^o San Francisco Clinical Research Center   (United States)

^p Octapharma AG   (Switzerland)

^q Octapharma Pharmazeutika Produktions GmbH   (Austria)

^r INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN; MEMANTINE; PLACEBO; AMYLOID BETA PROTEIN;

ACTINIC KERATOSIS; ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE FLUCTUATION; BRAIN HEMORRHAGE; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPEPSIA; FALLING; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GERMANY; HEADACHE; HEARING IMPAIRMENT; HEART ATRIUM FIBRILLATION; HEMATURIA; HIPPOCAMPUS; HUMAN; HYPERKERATOSIS; HYPERTENSION; HYPESTHESIA; HYPOTENSION; INJECTION SITE EXTRAVASATION; KNEE ARTHROPLASTY; LAMINECTOMY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA AND VOMITING; PARESTHESIA; PHASE 2 CLINICAL TRIAL; POSTLUMBAR PUNCTURE SYNDROME; POSTOPERATIVE COMPLICATION; POSTOPERATIVE DELIRIUM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; STOMACH ANTRUM VASCULAR ECTASIA; TREATMENT OUTCOME; TREMOR; UNITED STATES; BLOOD; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX;

MLCS; MLOWN;

EID: 84876307732     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70014-0     Document Type: Article

References (32)

1. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9:702-716.
2. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474.
3. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57:801-805.
4. Relkin NR Current state of immunotherapy for Alzheimer's disease. CNS Spectr 2008, 13:39-41.
5. Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736.
6. Gold R, Stangel M, Dalakas MC Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007, 3:36-44.
7. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002, 37:943-948.
8. Weksler M, Szabo P, Relkin N IVIG therapy of mild to moderate Alzheimer's disease patients showed significant benefits as measured by neuroimaging and neuropsychological testing in a phase II, randomized, double blind placebo controlled clinical study. Gerontologist 2010, 50:449-450.
9. Relkin N, Bettger L, Tsakanikas D, Ravdin L Three-year follow-up on the IVIG for Alzheimer's phase II study. Alzheimers Dement 2012, 8(suppl 4):P589.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
11. Folstein MF, Folstein SE, McHugh PR " Mini-mental state" . A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
12. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983, 17:37-49.
13. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
14. Blennow K, De Meyer G, Hansson O, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 2009, 13:205-208.
15. Gabrielsson J, Weiner D Pharmacokinetic & pharmacodynamic data analysis. Concepts and applications 2007, Swedish Pharmaceutical Press, Stockholm.
16. Morgan D Immunotherapy for Alzheimer's disease. J Intern Med 2011, 269:54-63.
17. Lemere CA, Masliah E Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol 2010, 6:108-119.
18. Scheltens P, Sperling R, Salloway S, Fox N Bapineuzumab IV phase 3 results. J Nutr Health Aging 2012, 16:797.
19. Doody RS Safety and efficacy of solanezumab in patients with mild to moderate Alzheimer's disease: results from phase 3. J Nutr Health Aging 2012, 16:801-802.
20. Relkin N, Gessert D, Stokes K, et al. The Gammaglobulin Alzheimer Partnership Study (GAP): design, screening, enrollment and futility analysis results. Alzheimers Dement 2012, 8(suppl):P456.
21. Sperling RA, Jack CR, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011, 7:367-385.
22. van der Vlies AE, Goos JD, Barkhof F, et al. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology 2012, 79:763-769.
23. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11:241-249.
24. Wittstock M, Zettl UK Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J Neurol 2006, 253(suppl 5):V75-V79.
25. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006, 155:714-721.
26. Mattsson N, Blennow K, Zetterberg H Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 2010, 48:603-607.
27. Herholz K Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. Biomark Med 2012, 6:431-439.
28. Chen K, Langbaum JB, Fleisher AS, et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 2010, 51:654-664.
29. Tschanz JT, Corcoran CD, Schwartz S, et al. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 2011, 19:532-542.
30. Williams MM, Storandt M, Roe CM, Morris JC Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement 2012, published online Aug 1. http://dx.doi.org/10.1016/j.jalz.2012.01.005.
31. Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000, 12:231-247.
32. Ito K, Corrigan B, Zhao Q, et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement 2011, 7:151-160.